IMPEDIMED LIMITED - Investor Presentation 2025

==> picture [230 x 54] intentionally omitted <==

ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: [email protected] W : impedimed.com

30 October 2025

Companies Announcements Office Australian Securities Exchange

Investor Presentation

ImpediMed Limited (ASX:IPD) releases the attached presentation to be delivered to investors and analysts today.

Approved for release by the Board of ImpediMed Limited.

For more information, contact Leanne Ralph, Company Secretary, at [email protected]

==> picture [109 x 21] intentionally omitted <==

Impedimed Limited Q1 FY26 Results October 2025

==> picture [380 x 291] intentionally omitted <==

Forward Lookin Statements g

This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited).

==> picture [94 x 18] intentionally omitted <==

A enda g

1 Business Overview

2 Financial Performance

3 H1 FY26 Outlook

==> picture [94 x 18] intentionally omitted <==

==> picture [109 x 21] intentionally omitted <==

Business Overview

==> picture [552 x 449] intentionally omitted <==

The SOZO[®] Di ital Health Platform Value Pro osition g p

Strong foundation

Best-in-class, FDA and TGA cleared, and CE-Marked cloud-based digital health platform measuring body composition and fluid outputs led by new Product Leadership

Addressing fast growing healthcare needs

Cancer Survivorship: Increasing focus in cancer survivorship programs
GLP-1-driven Weight Management: Growing understanding of the necessity to measure and maintain muscle mass
Heart Failure: Growing clinical and economic burden, with hospital readmission costs a key driver

Leverage investment across multiple indications

SOZO PRO and SOZO investment in multiple FDA clearances in BCRL, Body Comp and Heart Failure, including only BIS device cleared for unhealthy patients and patients with implantable cardiac devices
600 devices in leading US healthcare customers and 27 MSAs form strong platform for expansion
18 of the top 25 US hospitals
27 MSAs with major IDNs provide more than 1,400 hospital opportunities
Customer relationships provide referrals across hospital networks

==> picture [180 x 340] intentionally omitted <==

Completed IT assessments and contracts accelerate approvals
ImpediMed infrastructure can be leveraged across multiple applications

==> picture [94 x 18] intentionally omitted <==

Q1 Ke Hi hli hts y g g

Financial

Revenue $3.6m.
TCV $4.7m.
Annual recurring revenue $14.4m.
Quarterly operating cash outflow ($5.6m), inclusive of $1.1m one-off inventory component purchase.
Qualified for US$5.0m Tranche 2 of US$15.0m growth capital facility (drawn down).
Cash balance $23.0m, equating to 4.1 quarters of operating cash flow (5.3 quarters after excluding one-off payment).

Sales

45 SOZO units sold globally, up 1 unit compared to Q4 FY25.
U.S. 26 SOZO units
ROW 19 SOZO units
10% increase in TCV for U.S. contracts renewed in the quarter.

Reimbursement

Momentum continues with 87% national coverage, 304M covered lives.
6 additional commercial payors providing coverage, 2 of which are top-10 payors
Significantly increasing depth of coverage across multiple states:
Top 9 states in total population are now over 90% coverage.
Number of states above 80% coverage increased from 36 to 42.
Number of states above 90% coverage increased from 21 to 27.

==> picture [94 x 18] intentionally omitted <==

Breast Cancer Related L m hoedema y p

Lymphoedema underpinned for steady growth

Clinical demand remains strong.
Solid Foundation: 600+ SOZO devices deployed in the US and currently utilised in 18 of the top 25 US hospitals[1]
NCCN & NAPBC guideline inclusion: Broadening acceptance of cancer survivorship programs into oncology care.
Reimbursement increasing – 87% National Coverage: Newly published coverage significantly increases reimbursement in multiple key states.
Significant investment in sales team to positively impact sales in the medium term.

Key Accounts, IDNs, NAPBC and NCCN Centres remain a focus

High quality leading healthcare centres added and renewed in the quarter include Moffitt Cancer Centre, Mayo Clinic, University of Michigan, Ascension, Baylor Scott and White, Piedmont Health, Advent Health, Tenet Healthcare, RWJ Barnabas, University of Florida, University of Colorado, University of Chicago, Ohio State University, Arizona State University.
SOZOs in 24 of 33 NCCN Member Institutions with the addition of 1 new NCCN centre this quarter
Master Service Agreements (MSA) in place with 27 IDNs enabling rapid system wide expansion across >1400 identified opportunities.
Expansion within hospital systems is substantially faster once the first agreement covering BAA, T&C’s, Pricing and IT is established

Sales execution

Sufficient sales orders generated but final approvals impacted by delayed decision making within hospitals
Changes to sales team (3 new members) resulted in some short-term disruption

Renewals

Recent reimbursement wins continue to positively impact renewals and reduce potential churn
Average 10% increase in TCV of contracts renewed in the quarter.
Churn remains <3%

==> picture [94 x 18] intentionally omitted <==

https://rankings.newsweek.com/worlds-best-hospitals-2025/united-states-america Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2025 ImpediMed Limited.

Breast Cancer Related L m hoedema: Ke activities this uarter y p y q

Conferences

ASBrS Strategic Futures Form
ASCO Conquer Cancer Council Summit
McKesson Accelerate - US Oncology
AONN (Academy of Oncology Nurse & Patient Navigators)
Northern Arizona Healthcare Breast Symposium
Lynn Sage Breast Cancer Symposium

Breast cancer awareness month events

==> picture [377 x 197] intentionally omitted <==

Company supported several customer patient awareness events during Breast Cancer Awareness Month
Events held at Intermountain Healthcare, Rush Health and Mercy Medical
Webinar with Virginia Cancer Specialists, focusing on lymphedema surveillance & body composition monitoring for survivorship care
Presentation along with Essity, a leading global health company – Lymphedema Prevention including early detection & intervention

==> picture [94 x 18] intentionally omitted <==

Heart Failure

TAM estimated at $1.1bn for US outpatient heart failure fluid monitoring[1]
.
In the US, currently 6.7M HF patients which are expected to grow to 8.5M patients by 2030[2]

• SOZO Pro is the only bioimpedance device with:

US FDA and TGA clearance to support both in the assessment of fluid status in heart failure patients, as well as body composition assessment to support cardiac prehabilitation and rehabilitation.
US FDA clearance to measure patients with cardiac implantable devices (CIEDs) such as pacemakers and cardioverter -defibrillators (ICDs)

• US Go to Market activities commenced

Well received in recent meetings with US cardiologists and attendance at Texas Cardiology Conference
Targeted commercial pilots in progress
Reimbursed market - CPT code established and private payor coverage available in some key markets
Investigator initiated trials to support clinical adoption and increasing payor coverage
Based on a 30% share of the reimbursed market.
Bozkurt et al; Writing Committee Members. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail. 2023 Oct;29(10):1412-1451. doi: 10.1016/j.cardfail.2023.07.006. Epub 2023 Sep 26. PMID: 37797885; PMCID: PMC10864030.

==> picture [94 x 18] intentionally omitted <==

Body Comp

• Total Addressable Market

Current TAM: A$120m for clinical grade analysers within the US Hospital and Clinic market[1]
Potential TAM significantly larger when incorporate weight management market outside the US Hospital and Clinic segment
Currently ~15m Americans currently using a GLP-1 therapy, with a need to monitor and maintain muscle mass[2]
SOZO is the only bioimpedance device with:
US FDA clearance to measure body composition in an unhealthy patient population
US FDA clearance to measure body composition to support cardiac rehab patients with cardiac implantable devices
Clinical guidelines recommending bioimpedance as a validated tool to measure body comp
The Lancet Diabetes & Endocrinology Commission[3] , included bioimpedance as an objective measurement technique to be used in assessing obesity
The Obesity Society[4] includes bioimpedance as a validated tool to support assessment of muscle mass during weight loss through pharmacotherapy

• US Go-to-Market activities commenced – measured expansion into BC for HF and medically managed weight loss in a clinical setting

  - Positive feedback on product and commercial model for non reimbursed (out of pocket) market generated in the quarter

  - Over 300 leads created this quarter and attending 3 large conferences this quarter to generate additional opportunities

2 new dedicated body comp reps
Global Body Composition Analyzers Market Mordor Intelligence
https://www.fortunebusinessinsights.com/glp-1-receptor-agonist-market
Rubino, Francesco et al. Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes & Endocrinology, Volume 13, Issue 3, 221 – 262
Mozzafarian et al. Nutritional priorities to support GLP-1 therapy for obesity: a Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition Volume 122, Issue 1, July 2025, Pages 344-367

==> picture [94 x 18] intentionally omitted <==

==> picture [552 x 449] intentionally omitted <==

==> picture [109 x 21] intentionally omitted <==

Financial Performance

Cash Flow

Summarized Cash Flow	FY26	• • • • •
In thousands	Q1
AUD Receipts from customers Research & development Product manufacturing & operating costs Advertising costs Staff costs Administration and corporate costs Government grants and tax incentives Other operating	Actual 3,443 (62) (1,538) (324) (4,939) (2,184) - 2
Net operating cash in/(out)flow:	(5,602)
Interest received Purchase of intangibles	252 (178)
Net investing cash in/(out)flow:	74
Transaction costs from capital raise Proceeds from borrowings Interest paid Operatingleases	- 7,676 (623) (91)
Net financing cash in/(out)flow:	6,962

Net cash in/(out)flow:	1,434
Net foreign exchange differences Cash at beginningofperiod	(694) 22,249
Cash at close ofperiod	22,989

Q1 operating cash outflow of $5.6m:

Including previously announced one-off $1.1m payment for key electronic components.
Q2 operating cash outflow expected to reduce to ~$3.0m (includes forecast increased receipts from customers, receipt of R&D tax offset and no recurrence of one-off payment).

Quarterly customer cash receipts of $3.4m.

Strengthening AUD relative to USD resulted in an unrealised FX loss of $0.7m.

Remaining $US5.0m of the $US15.0m debt facility drawn.

Net cash balance $A23.0m:
Equal to 4.1 quarters of operating cashflow
Equal to 5.3 quarters of operating cashflow excluding the one-time payment for key electronic components.

==> picture [94 x 18] intentionally omitted <==

TCV and ARR

SOZO Core Business Quarterly Total Contract Value1 A$ millions

SOZO Annual Recurring Revenue2 A$ millions

TCV of $4.7m down 25% vs. Q4 FY25.
ARR up 24% vs Q1 FY25; up 3% vs prior quarter.
Smaller number of customers due for renewal in the quarter.
ARR continues to grow as quarterly TCV gains translate into revenue.

• Renewed contracts price increased 10% on average.

• Stronger AUD reduced translated ARR.

1.Total Contracted Value (TCV) relates to new and renewed contracts and includes any consideration for the sale of SOZO units as well as the total licence fees for the duration of the signed contracts. Typically, these contracts are for a period of three years.

2.Annual Recurring Revenue (ARR) represents the amount of revenue reasonably expected to be recognised for the next 12-month period based on existing contracts, assuming installation upon sale and no churn. The amounts shown are as reported. The exchange rate used for Q1 FY26 ARR calculation was 0.6543 (Q4 FY25: 0.6434).

==> picture [94 x 18] intentionally omitted <==

Revenue and Cash Recei ts p

Revenue

A$ millions

Cash Receipts A$ millions

==> picture [324 x 266] intentionally omitted <==

Q1 FY26 revenue up 7% vs. Q4 FY25.
Q1 North America revenue up 6% vs. Q4 FY25; ROW up 50%.
Stronger AUD reduced translated US revenue.
Cash receipts of $3.4m, up 26% vs. Q1 FY25.
Q1 operating cash outflow of $5.6m, favorable vs. forecast.
Cash to fund 4.1 quarters of operating cashflow.

==> picture [94 x 18] intentionally omitted <==

Global Installed Base and Patient Test Numbers

Global Installed Base

Units

ROW Installed Base U.S. Installed base

Patient Tests (000s)

==> picture [103 x 55] intentionally omitted <==

----- Start of picture text -----

16%
3-year CAGR [1]
----- End of picture text -----

45 SOZO units sold vs 44 Q4 FY25
U.S. unit sales: 26 vs. 44 in Q4 FY25
77,000 Patient tests in Q1 FY26
Up 4% vs. Q4 FY25
19 ROW units in Q1 FY26 vs. 0 in Q4 FY25

• Churn remains low at <3% p.a.

1.Compound Annual Growth Rate. Quarterly patient tests Q1 FY23 to Q1 FY26

==> picture [94 x 18] intentionally omitted <==

==> picture [109 x 21] intentionally omitted <==

Outlook for H1 FY26

==> picture [552 x 449] intentionally omitted <==

U dated Outlook for H1 FY26 p

❑ Grow US BCRL sales leveraging changes to sales team and expanded reimbursement

Lymphoedema awareness activities generate leads
o Improvement in lead conversions to sales
Fill remaining open territory

❑ Expand Lymphoedema payor coverage ❑ Body Comp

Grow sales in oncology and clinically managed weight loss
o Refine the Body Comp product offering to best fit customer needs

❑ Heart Failure

US commercial pilots and sales through ANZ distributor
Investigator-initiated trials to accelerate clinical adoption and reimbursement expansion
❑ Optimise Lymphoedema Prevention Programs (LPP) to support customer utilisation and renewals ❑ Continue to tightly control costs to accelerate path to break even

==> picture [94 x 18] intentionally omitted <==

==> picture [184 x 36] intentionally omitted <==

AI assistant

IMPEDIMED LIMITED — Investor Presentation 2025

65135_rns_2025-10-29_7bc943c3-bc33-4f14-9482-e96d5adafb17.pdf

Investor Presentation

Approved for release by the Board of ImpediMed Limited.

Forward Lookin Statements g

A enda g

Business Overview

The SOZO[®] Di ital Health Platform Value Pro osition g p

Strong foundation

Addressing fast growing healthcare needs

Leverage investment across multiple indications

Q1 Ke Hi hli hts y g g

Financial

Sales

Reimbursement

Breast Cancer Related L m hoedema y p

Lymphoedema underpinned for steady growth

Key Accounts, IDNs, NAPBC and NCCN Centres remain a focus

Sales execution

Renewals

Breast Cancer Related L m hoedema: Ke activities this uarter y p y q

Conferences

Breast cancer awareness month events

Heart Failure

• SOZO Pro is the only bioimpedance device with:

• US Go to Market activities commenced

Body Comp

• Total Addressable Market

• US Go-to-Market activities commenced – measured expansion into BC for HF and medically managed weight loss in a clinical setting

Financial Performance

Cash Flow

Q1 operating cash outflow of $5.6m:

Quarterly customer cash receipts of $3.4m.

TCV and ARR

• Renewed contracts price increased 10% on average.

• Stronger AUD reduced translated ARR.

Revenue and Cash Recei ts p

Revenue

Global Installed Base and Patient Test Numbers

Global Installed Base

Patient Tests (000s)

• Churn remains low at <3% p.a.

Outlook for H1 FY26

U dated Outlook for H1 FY26 p

❑ Grow US BCRL sales leveraging changes to sales team and expanded reimbursement

❑ Expand Lymphoedema payor coverage ❑ Body Comp

❑ Heart Failure

More from IMPEDIMED LIMITED

IMPEDIMED LIMITED Investor Presentation 2025